Bristol-Myers Halts Clinical Trials Over Patient Safety Concerns

Bristol-Myers Squibb announced it has suspended clinical trials of a drug in development for the treatment of hepatitis C.

Advertisement

 

Sign up for our FREE E-Weekly for more coverage like this sent to your inbox!

The company halted the clinical trials due to “the emergence of a serious safety issue,” though officials stayed mum on the exact risk posed to patients.

More Articles on Patient Safety:

3 Ways Healthcare Quality Data Can Be Misleading

ASCA Publishes Quality Measure Reporting FAQs

CMS Adds Imaging Efficiency Measures to Hospital Compare

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Uncategorized

Advertisement

Comments are closed.